Trial · NCT02507011

Beta-blockers in Pulmonary Arterial Hypertension

NCT02507011, Phase 2, Terminated, University of Minnesota; results first posted 2020-06-16

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Beta-blockers in Pulmonary Arterial Hypertension. Trials, record NCT02507011. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02507011

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Beta-blockers in Pulmonary Arterial Hypertension
NCT number: NCT02507011
Status: Terminated
Phases: Phase 2
Enrollment: 2 participants, actual
Lead sponsor: University of Minnesota
Conditions: Pulmonary Arterial Hypertension
Interventions: Carvedilol, Placebo
First posted: 2015-07-23
Last updated: 2020-06-16
Results first posted: 2020-06-16

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Mean Change in Right Ventricular Ejection Fraction as Measured by Cardiac MRI	6 months

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Mean Change in Right Ventricular Ejection Fraction as Measured by Cardiac MRI	6 months		percent	MEAN

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Mean Change in Right Ventricular Ejection Fraction as Measured by Cardiac MRI	Carvedilol		10	Standard Deviation 4	percent
Mean Change in Right Ventricular Ejection Fraction as Measured by Cardiac MRI	Placebo		2.5	Standard Deviation 2	percent

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
First Intervention	STARTED	Carvedilol First, Then Placebo	1
First Intervention	STARTED	Placebo First, Then Carvedilol	1
First Intervention	COMPLETED	Carvedilol First, Then Placebo	1
First Intervention	COMPLETED	Placebo First, Then Carvedilol	1
First Intervention	NOT COMPLETED	Carvedilol First, Then Placebo	0
First Intervention	NOT COMPLETED	Placebo First, Then Carvedilol	0
Second Intervention	STARTED	Carvedilol First, Then Placebo	1
Second Intervention	STARTED	Placebo First, Then Carvedilol	1
Second Intervention	COMPLETED	Carvedilol First, Then Placebo	1
Second Intervention	COMPLETED	Placebo First, Then Carvedilol	1

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events12

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Fatigue	General disorders	Carvedilol	1	2	1
other	Fatigue	General disorders	Placebo	1	2	1
other	Hypotension	General disorders	Carvedilol	1	2	1
other	Hypotension	General disorders	Placebo	0	2	0
other	Fluid Retention	General disorders	Carvedilol	1	2	1
other	Fluid Retention	General disorders	Placebo	1	2	1
other	Constipation	Gastrointestinal disorders	Carvedilol	0	2	0
other	Constipation	Gastrointestinal disorders	Placebo	1	2	2
other	Gastroenteritis	Gastrointestinal disorders	Carvedilol	0	2	0
other	Gastroenteritis	Gastrointestinal disorders	Placebo	1	2	2

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Carvedilol	0	2
Total, all-cause mortality	Placebo	0	2
Total, other adverse events	Carvedilol	1	2
Total, other adverse events	Placebo	2	2
Total, serious adverse events	Carvedilol	1	2
Total, serious adverse events	Placebo	1	2

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Carvedilol vs Placebo: deaths from any cause	Trial comparisons
Carvedilol vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02507011

GET https://conductscience.org/api/trials/v1/NCT02507011/registered

API reference For AI assistants